A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised participants with COVID-19 (The COVASE trial)
Latest Information Update: 12 Jun 2020
At a glance
- Drugs Dornase alfa (Primary)
- Indications COVID 2019 infections; Respiratory tract disorders
- Focus Therapeutic Use
- Acronyms COVASE
Most Recent Events
- 12 Jun 2020 New trial record